We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Moderna is offering its COVID-19 vaccine candidate at $32 to $37 per dose for smaller-scale supply agreements, the company’s CEO Stéphane Bancel said Wednesday. Read More
Johnson & Johnson (J&J) has secured a $1 billion contract from the U.S. government to manufacture 100 million doses of its COVID-19 vaccine candidate Ad26.COV2.S. Read More
Sun Pharmaceuticals announced that it has launched its generic version of the antiviral drug Avigan (favipiravir) in India, setting a 47 cent price tag per tablet. Read More
Novavax has announced preliminary data from a phase 1 trial of its COVID-19 vaccine NVX-CoV2373 in Australia that showed the vaccine generated a strong immune response. Read More
The National Institutes of Health (NIH) launched two clinical trials yesterday of Eli Lilly’s experimental monoclonal antibody LY-CoV555 for the treatment for COVID-19 patients. Read More
The head of the World Health Organization (WHO) cautioned Monday that no “silver bullet” for the coronavirus may emerge from the flurry of potential vaccines entering phase 3 trials. Read More
RSS
